Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: Lizza Hendriks Clear advanced filters

  • Patients with unresectable stage III non-small-cell lung cancer without EGFR or ALK mutations typically receive the PACIFIC regimen — concurrent chemoradiotherapy (cCRT) followed by consolidation with durvalumab — whereas those with EGFR-mutant disease typically receive cCRT followed by an EGFR inhibitor. Nonetheless, a subset of patients within this heterogeneous group might be able to completely avoid consolidation therapy, whereas others are unable to tolerate cCRT. In this Review, the authors describe the standard-of-care approach in this setting, followed by discussions of treatment optimization for specific subgroups, as well as important future research questions.

    • Jordi Remon
    • Antonin Levy
    • Maurice Pérol
    Reviews
    Nature Reviews Clinical Oncology
    P: 1-18

  • Activating immune cells to destroy tumours is an effective strategy for treating an advanced lung cancer — but only for some people. Evidence that this approach has potential in early disease and as a combination therapy has now emerged.

    • Lizza Hendriks
    • Benjamin Besse
    News & Views
    Nature
    Volume: 558, P: 376-377

  • Correct interpretation of computer tomography (CT) scans is important for the correct assessment of a patient’s disease but can be subjective and timely. Here, the authors develop a system that can automatically segment the non-small cell lung cancer on CT images of patients and show in an in silico trial that the method was faster and more reproducible than clinicians.

    • Sergey P. Primakov
    • Abdalla Ibrahim
    • Philippe Lambin
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-12

  • Non-small-cell lung cancer accounts for ~85% of lung cancers. In this Primer, Hendriks et al. summarize current knowledge and research on this malignancy, discussing its epidemiology, mechanisms, diagnosis and management, as well as quality of life and future research directions.

    • Lizza E. L. Hendriks
    • Jordi Remon
    • Martin Reck
    Reviews
    Nature Reviews Disease Primers
    Volume: 10, P: 1-22

  • The lungs are a common metastatic site for several cancers, including colorectal cancer, primary lung cancer, breast cancer and prostate cancer. This Primer summarizes the epidemiology, mechanisms and diagnosis of lung metastasis, discusses the various treatment options and effects on quality of life, and highlights ongoing and future research areas.

    • Lodovica Zullo
    • Dimitris Filippiadis
    • Benjamin Besse
    Reviews
    Nature Reviews Disease Primers
    Volume: 11, P: 1-19

  • Several trials are testing immune-checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, in patients with resectable non-small-cell lung cancer as an adjuvant, neoadjuvant or perioperative approach. However, the optimal use of ICIs with curative intent in patients with early stage non-small-cell lung cancer remains unclear. The authors of this Review discuss the current trial landscape and discuss challenges and opportunities.

    • Giannis Mountzios
    • Jordi Remon
    • Solange Peters
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 20, P: 664-677